ImmunOs Therapeutics AG

Novel human immunomodulatory proteins for cancer and autoimmune diseases with a specific role in innate immunity

Add To Watchlist
General Information
Company Name
ImmunOs Therapeutics AG
Founded Year
2014
Location (Offices)
Schlieren, Switzerland +1
Founders / Decision Makers
Sean R. Smith - Chief Executive Officer Christoph Renner - Chief Medical Officer Steve Coats - Chief Development Officer Osiris Marroquin Belaunzaran - Founder & Chief Scientific Officer Jeff Abbey - COO
Number of Employees
15
Industries
Biotechnology, Health Care, Pharmaceutical
Funding Stage
Series B
Social Media

ImmunOs Therapeutics AG - Company Profile

ImmunOs Therapeutics AG is a Swiss-based biotechnology company founded in 2014. The company specializes in developing novel human immunomodulatory proteins for cancer and autoimmune diseases, focusing on the innate immune system. Their lead program, iosH2, has shown promise in activating anti-tumor responses in various cancers and is now advancing to Phase 1 studies. ImmunOs Therapeutics aims to not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies.

The company recently received a significant Fr.71.00M Series B investment on 07 June 2022. The round was led by prominent investors including Lightspeed Venture Partners, Redalpine, BioMed Partners, GL Capital, Mission BioCapital, Peak 6, Samsara BioCapital, Schroder Adveq, Pfizer Venture Investments, and Fiscus Financial. This investment signifies the confidence that the venture capital community has in ImmunOs Therapeutics and its innovative approach to immunotherapy.

ImmunOs Therapeutics AG operates in the biotechnology, healthcare, and pharmaceutical industries and is poised to make a significant impact in the field of cancer and autoimmune disease treatment with its unique immunomodulatory proteins. With the latest investment, the company is well-positioned to further advance its research and development efforts and bring its promising therapies to market, potentially transforming the way these diseases are treated.

Taxonomy: Immunotherapy, Cancer treatment, Autoimmune diseases, Innate immunity, Immunomodulatory proteins, Tumor microenvironment remodeling, Phase 1 studies, LILRB receptors, Checkpoint inhibitors, Costimulatory agonists, Cancer immunotherapy, Innate immune system, Biopharmaceuticals, Clinical trials, Therapeutics development

Funding Rounds & Investors of ImmunOs Therapeutics AG (6)

View All
Funding Stage Amount No. Investors Investors Date
Series B Fr.71.00M 10
Lightspeed Venture Partners, investor in ImmunOs Therapeutics AG's Series B round GIMV, investor in ImmunOs Therapeutics AG's Series B round Redalpine, investor in ImmunOs Therapeutics AG's Series B round Mission BioCapital, investor in ImmunOs Therapeutics AG's Series B round Peak 6, investor in ImmunOs Therapeutics AG's Series B round Samsara BioCapital, investor in ImmunOs Therapeutics AG's Series B round Schroder Adveq, investor in ImmunOs Therapeutics AG's Series B round GL Capital Group, investor in ImmunOs Therapeutics AG's Series B round
Pfizer Venture Investments, Fiscus Financial 		07 Jun 2022
Grant Unknown 2
Innosuisse, investor in ImmunOs Therapeutics AG's Grant round European Union, investor in ImmunOs Therapeutics AG's Grant round
12 Apr 2021
Series A Fr.15.00M 8
Redalpine, investor in ImmunOs Therapeutics AG's Series A round BioMed Partners, investor in ImmunOs Therapeutics AG's Series A round Schroder Adveq, investor in ImmunOs Therapeutics AG's Series A round Wille AG, investor in ImmunOs Therapeutics AG's Series A round Bernina BioInvest, investor in ImmunOs Therapeutics AG's Series A round
Reinhard Ambros, Pfizer Venture Investments +1 		10 Dec 2019
Venture Round Unknown 2
Schroder Adveq, investor in ImmunOs Therapeutics AG's Venture Round round UZH Foundation – Die Stiftung der Universität Zürich, investor in ImmunOs Therapeutics AG's Venture Round round
01 Oct 2018
Seed Round Fr.2.30M - 08 Dec 2017

View All 6 Funding Rounds

Latest News of ImmunOs Therapeutics AG

View All

No recent news or press coverage available for ImmunOs Therapeutics AG.

Similar Companies to ImmunOs Therapeutics AG

View All
Umoja Biopharma - Similar company to ImmunOs Therapeutics AG
Umoja Biopharma Pioneering advanced immunotherapies to empower the body's innate ability to fight cancer by reengineering immune cells directly within the patient.
Turnstone Biologics - Similar company to ImmunOs Therapeutics AG
Turnstone Biologics Developing next-generation TIL-based therapies to treat and cure solid tumors.
Imvax, Inc. - Similar company to ImmunOs Therapeutics AG
Imvax, Inc. Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies.
Trillium Therapeutics Inc. - Similar company to ImmunOs Therapeutics AG
Trillium Therapeutics Inc. Clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer.
Mablytics, Inc. - Similar company to ImmunOs Therapeutics AG
Mablytics, Inc. Innovation that delivers
Circle Decoration Circle Decoration

Want to dive deeper into ImmunOs Therapeutics AG? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now